- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04855981
Whole-body Vibration Versus Aerobic Exercise on the Inflammatory Status and Hormonal Parameters Premenstrual Syndrome (PMS)
February 2, 2024 updated by: Al Shaymaa Shaaban Abd El Azeim, Cairo University
Effect of Whole-body Vibration Versus Aerobic Exercise on the Inflammatory Status and Hormonal Parameters in Females With Premenstrual Syndrome
The purpose of this study is to investigate and compare the effect of whole-body vibration to aerobic exercise on inflammatory status in females with premenstrual syndrome.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Premenstrual syndrome (PMS) is a complex disorder characterized by moderate to severe symptoms taking place during the luteal phase of the menstrual cycle.
It has a negative impact on females' lives, which can affect their relationships, educational efficiency, social activities, and quality of life.
Despite previous studies reported that physical exercise improves the symptoms of PMS, the effects of physical exercise on inflammatory status in females with PMS are not clear yet.
sixty females allocated to three groups randomly to group (A) that will receive whole-body vibration+supplementation, group (B) that will receive aerobic exercises+supplementation, and group c that will receive supplementation only
Study Type
Interventional
Enrollment (Actual)
105
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Giza, Egypt, 12511
- Al Shaymaa Shaaban Abd El Azeim
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 25 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Females suffering from PMS (as determined by PMS scale).
- Their ages will range from 18 to 25 years.
- Having regular menstrual cycle.
Exclusion Criteria:
- Smoking.
- Taking any medications.
- History of chronic disease.
- Having any psychiatric or gynecological problems
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: whole body vibration
the subjects will receive whole-body vibration three times per week for twelve weeks +supplementations
|
All participants in the WBV group will perform the WBV training on a vibrating device (Confidence Vibration Plate Power Plus, China), which produces a lateral peak-to-peak oscillation.
They will stand on the WBV platform with a 150° knee angle during the exposure minute.
They started the training with three sets of 1 min separated by a 1-min resting period and vibration amplitude of 1 mm.
They will add one set every session until they performed 10 sets of WBV.
The frequency started at 20 Hz, which will be increased gradually by 2 Hz every 2 weeks +magnesium (Mg) (250 g) and vitamin B6 supplementation
the subjects will receive magnesium (Mg) (250 g) and vitamin B6 supplementation
|
Experimental: aerobic exercise
the subjects will receive aerobic exercise three times per week for twelve weeks+supplementations
|
the subjects will receive magnesium (Mg) (250 g) and vitamin B6 supplementation
the subjects will receive aerobic exercises+ magnesium (Mg) (250 g) and vitamin B6 supplementation
|
Active Comparator: supplementations
the subjects will receive supplementations three times per week for twelve weeks
|
the subjects will receive magnesium (Mg) (250 g) and vitamin B6 supplementation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
premenstrual symptoms
Time Frame: up to twelve weeks
|
The premenstrual syndrome questionnaire also measured the occurrence and severity of two menstrual pain symptoms, including cramp and backache experienced during the first 2 days of the women' last menstrual period.
Premenstrual symptoms were scaled as: mild (1); moderate (2); and severe (3).
Young women with PMS should experience a premenstrual symptoms score of at least 50% greater than the postmenstrual score
|
up to twelve weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CRP level assessment
Time Frame: up to twelve weeks
|
blood sampl a normal reading is less than 10 milligram per liter (mg/L), more than 10 milligram the level of inflammation in body increase.
|
up to twelve weeks
|
cortisol level
Time Frame: up to twelve weeks
|
When a technician carries out the cortisol level test between 6 a.m. and 8 a.m., the results will typically be within the range of 10-20 micrograms per deciliter (mcg/dL).
more than 20 the level of stress increased.
|
up to twelve weeks
|
hormonal analysis
Time Frame: up to twelve weeks
|
blood sample will be used for assessment the level of progesterone and prolactin.
normal level of progesterone less than 0.20 ng/mL and Normal levels of prolactin in females: less than 25 ng/mL
|
up to twelve weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 15, 2021
Primary Completion (Actual)
May 30, 2022
Study Completion (Actual)
May 30, 2022
Study Registration Dates
First Submitted
April 7, 2021
First Submitted That Met QC Criteria
April 20, 2021
First Posted (Actual)
April 22, 2021
Study Record Updates
Last Update Posted (Actual)
February 5, 2024
Last Update Submitted That Met QC Criteria
February 2, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- p.t.REC/012/003183
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Premenstrual Syndrome
-
Esra ÖZERKTO Karatay UniversityRecruitingPremenstrual Syndrome-PMSTurkey
-
Shaare Zedek Medical CenterUnknownPremenstrual Syndrome-PMS
-
Philipps University Marburg Medical CenterLinkoeping UniversityCompletedPremenstrual Syndrome (PMS)Germany
-
Cairo UniversityNot yet recruitingPremenstrual Tension
-
Cairo UniversityNot yet recruitingPremenstrual Pain
-
Terra Biological LLCCompletedPremenstrual Syndrome (PMS)
-
Massachusetts General HospitalWithdrawnPremenstrual Dysphoric Disorder | Premenstrual Syndrome | Premenstrual Tension | Menstrual Related Mood DisorderUnited States
-
Tel-Aviv Sourasky Medical CenterUnknownDepression | Premenstrual Dysphoric Disorder (PMDD)Israel
-
Yale UniversityNational Institute of Mental Health (NIMH)CompletedPremenstrual SyndromeUnited States
Clinical Trials on whole body vibration
-
Gazi UniversityGulhane Training and Research HospitalRecruitingArthropathy of Knee | Whole-body Vibration | Swelling/ EdemaTurkey
-
The Hong Kong Polytechnic UniversityUnknown
-
The Hong Kong Polytechnic UniversityCompleted
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityCompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Chemotherapy-Induced Peripheral NeuropathyUnited States
-
University of the Balearic IslandsUnknown
-
Schön Klinik Berchtesgadener LandCompletedChronic Obstructive Pulmonary DiseaseGermany
-
University of SevilleAsociación de Enfermos de Parkinson de SevillaNot yet recruiting
-
University of CologneCompleted
-
Florida State UniversityCompleted